Mark C. Totoritis
- Rheumatology top 0.5%
- Immunology top 5%
- Radiology, Nuclear Medicine and Imaging top 2%
- Genetics top 2%
- Hematology top 2%
- Co-authors
- Edward KeystoneMaxime DougadosMark C. GenoveseE. HesseyMaria GreenwaldRichard FuriePaul EmeryGerd‐Rüdiger Burmester
- Topics
- Systemic Lupus Erythematosus Research (7 papers)Monoclonal and Polyclonal Antibodies Research (6 papers)T-cell and B-cell Immunology (3 papers)
- Cited by
- RheumatologyGeneticsImmunology
- Journals
- New England Journal of MedicineThe Journal of ImmunologyJournal of Allergy and Clinical Immunology
- Partner nations
- United StatesUnited KingdomRomania
In The Last Decade
Mark C. Totoritis
15 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Rheumatology 1.2k
- Immunology 872
- Radiology, Nuclear Medicine and Imaging 645
- Genetics 466
- Hematology 430
Countries citing papers authored by Mark C. Totoritis
This map shows the geographic impact of Mark C. Totoritis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Totoritis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Totoritis more than expected).
Fields of papers citing papers by Mark C. Totoritis
This network shows the impact of papers produced by Mark C. Totoritis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Totoritis. The network helps show where Mark C. Totoritis may publish in the future.
Co-authorship network of co-authors of Mark C. Totoritis
This figure shows the co-authorship network connecting the top 25 collaborators of Mark C. Totoritis. A scholar is included among the top collaborators of Mark C. Totoritis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark C. Totoritis. Mark C. Totoritis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 60 | |
| 2 | 18 | |
| 3 | Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksbreakdown → | 1267 |
| 4 | 35 | |
| 5 | 15 | |
| 6 | 27 | |
| 7 | 266 | |
| 8 | CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. | 40 |
| 9 | Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. | 121 |
| 10 | 52 | |
| 11 | 119 | |
| 12 | 33 | |
| 13 | 82 | |
| 14 | 26 | |
| 15 | 5 |
About Mark C. Totoritis
Mark C. Totoritis is a scholar working on Rheumatology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 15 papers that have together received 2.2k indexed citations. Recurring topics across this work include Systemic Lupus Erythematosus Research (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and T-cell and B-cell Immunology (3 papers). The work is most often cited by research in Rheumatology (1.2k citations), Genetics (466 citations) and Immunology (872 citations). Mark C. Totoritis has collaborated with scholars based in United States, United Kingdom and Romania. Frequent co-authors include Edward Keystone, Maxime Dougados, Mark C. Genovese, E. Hessey, Maria Greenwald, Richard Furie, Paul Emery, Gerd‐Rüdiger Burmester, Stanley Cohen and Matthew Cravets. Their work appears in journals such as New England Journal of Medicine, The Journal of Immunology and Journal of Allergy and Clinical Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.